Semi-empirical anticoagulation model (SAM): INR monitoring during Warfarin therapy Marco Bontempi Original Paper 15 October 2021 Pages: 271 - 282
Improving categorical endpoint longitudinal exposure–response modeling through the joint modeling with a related endpoint Chuanpu HuHonghui Zhou Original Paper 20 November 2021 Pages: 283 - 291
R-praziquantel integrated population pharmacokinetics in preschool- and school-aged African children infected with Schistosoma mansoni and S. haematobium and Lao adults infected with Opisthorchis viverrini Christine FalcozSerge GuzyJennifer Keiser Original Paper 13 January 2022 Pages: 293 - 310
Prediction of CYP-mediated silybin A-losartan pharmacokinetic interactions using physiological based pharmacokinetic modeling Ayesha TanveerKhalid HussainNadeem Irfan Bukhari Original Paper 21 January 2022 Pages: 311 - 323
Physiologically-based pharmacokinetic model for 2,4-dinitrophenol Lyndsey F. MeyerPooja M. RajadhyakshaDhaval K. Shah Original Paper 28 January 2022 Pages: 325 - 336
Towards a translational physiologically-based pharmacokinetic (PBPK) model for receptor-mediated transcytosis of anti-transferrin receptor monoclonal antibodies in the central nervous system Hsueh-Yuan ChangShengjia WuDhaval K. Shah Original Paper 29 January 2022 Pages: 337 - 362
A pharmacokinetic and pharmacodynamic analysis of drug forgiveness Noel P. McAllisterSean D. Lawley Original Paper 13 February 2022 Pages: 363 - 379
Integrated multiple analytes and semi-mechanistic population pharmacokinetic model of tusamitamab ravtansine, a DM4 anti-CEACAM5 antibody-drug conjugate Clemence PouzinLeonid GibianskyLaurent Nguyen Original Paper Open access 15 February 2022 Pages: 381 - 394
Correction to: R-praziquantel integrated population pharmacokinetics in preschool- and school-aged African children infected with Schistosoma mansoni and S. haematobium and Lao adults infected with Opisthorchis viverrini Christine FalcozSerge GuzyJennifer Keiser Correction 04 February 2022 Pages: 395 - 395
